<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="308025">
  <stage>Registered</stage>
  <submitdate>8/06/2009</submitdate>
  <approvaldate>17/06/2009</approvaldate>
  <actrnumber>ACTRN12609000477224</actrnumber>
  <trial_identification>
    <studytitle>A Prospective Observational Study Reviewing the Incidence of Nail Changes in Patients Receiving Docetaxel- Based Chemotherapy</studytitle>
    <scientifictitle>A Prospective Observational Study Reviewing the Incidence of Nail Changes in Breast Cancer Patients Receiving Docetaxel- Based Chemotherapy</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nail study</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cutaneous toxicity</healthcondition>
    <healthcondition>Breast cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Breast</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Observational study of nail changes in patients receiving docetaxel based chemotherapy over approx. 6 months.
Dose, mode of administration and frequency of treatment with docetaxel are dependent upon the docetaxel chemotherapy regimen chosen. This will be at the discretion of the clinician and details will be recorded for each treatment cycle .</interventions>
    <comparator>Observational study</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Assess frequency and severity of nail changes in women with early breast cancer receiving docetaxel based chemotherapy, using patient observation,clinician assessment and photographs.</outcome>
      <timepoint>Outcome measured at baseline,on day 1 of each chemotherapy cycle and at each follow-up visit until trial conclusion estimated to be 2011</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Assess impact of nail changes functionally and cosmetically,using patient self reports and questionaires.</outcome>
      <timepoint>Outcome measured at baseline,on day 1 of each chemotherapy cycle and at each follow-up visit until trial conclusion estimated to be 2011</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Describe current treatment practices for management of nail changes in Australia,using patient interviews and questionaires.</outcome>
      <timepoint>Outcome measured at baseline,on day 1 of each chemotherapy cycle and at each follow-up visit until trial conclusion estimated to be 2011.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Women with early breast cancer receiving adjuvent docetaxel based chemotherapy for at least 3 cycles of chemotherapy.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Serious intercurrent illness or psychological,sociological, geographical conditions which would preclude adequate follow up and compliance with the protocol.
Pre-existing nail conditions.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>5/06/2009</anticipatedstartdate>
    <actualstartdate>5/06/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate>27/07/2010</actualenddate>
    <samplesize>150</samplesize>
    <actualsamplesize>14</actualsamplesize>
    <currentsamplesize />
    <recruitmentstatus>Stopped early</recruitmentstatus>
    <anticipatedlastvisitdate>27/07/2010</anticipatedlastvisitdate>
    <actuallastvisitdate>27/07/2010</actuallastvisitdate>
    <dataanalysis>No data analysis planned</dataanalysis>
    <withdrawnreason>Lack of funding/staff/facilities</withdrawnreason>
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>WA</recruitmentstate>
    <hospital>Mount Hospital - Perth</hospital>
    <postcode>6000 - Perth</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr Arlene Chan</primarysponsorname>
    <primarysponsoraddress>Mount Clinical Trials 
Suite 22, Level 2
146 Mounts Bay Rd
Perth, WA 6000</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Sanofi Aventis</fundingname>
      <fundingaddress>Talavera Corporate Centre
Building D
12-24 Talavera Rd
Macquarie Park
NSW 2113</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>assessment of nail changes to patients undergoing chemotherapy with taxotere. Nail bed toxicity was assessed by physical examination, questionnaire completion and photographs. Study participation during chemotherapy treatment and up to 3 months post chemotherapy. </summary>
    <trialwebsite />
    <publication>no publication or analysis was done on this trial</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Mount Hospital Ethics Comittee</ethicname>
      <ethicaddress>150 Mounts Bay Rd
Perth, 
WA 6000</ethicaddress>
      <ethicapprovaldate>5/02/2008</ethicapprovaldate>
      <hrec>E.C. 44.7</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Mrs</title>
      <name>Jeannette Devoto</name>
      <address>Hollywood Private Hospital
Entrance 3, Lower Ground Floor
101 Monash Avenue
Nedlands WA 6009</address>
      <phone>+61 8 6500 5555</phone>
      <fax />
      <email>BCTU@bcrc-wa.com.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Mrs</title>
      <name>Jeannette Devoto</name>
      <address>Hollywood Private Hospital 
Entrance 3, Lower Ground Floor
101 Monash Avenue
Nedlands WA 6009</address>
      <phone>+ 61 8 6500 5555</phone>
      <fax />
      <email>BCTU@bcrc-wa.com.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Jeannette Devoto</name>
      <address>Hollywood Private Hospital
Entrance 3, Lower Ground Floor
101 Monash Avenue
Nedlands WA 6009</address>
      <phone>+ 61 8 6500 5555</phone>
      <fax>+ 61 8 6500 5599</fax>
      <email>BCTU@bcrc-wa.com.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Arlene Chan</name>
      <address>Hollywood Private Hospital
Entrance 3, Lower Ground Floor
101 Monash Avenue
Nedlands WA 6009</address>
      <phone>+ 61 8 6500 5555</phone>
      <fax />
      <email>admin.arlenechan@me.com</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>